{"id":23473,"date":"2022-12-20T21:21:00","date_gmt":"2022-12-20T13:21:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23473"},"modified":"2025-01-27T21:24:41","modified_gmt":"2025-01-27T13:24:41","slug":"pcaob-report-signals-relief-for-us-listed-chinese-biotechs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23473","title":{"rendered":"PCAOB Report Signals Relief for US-Listed Chinese Biotechs"},"content":{"rendered":"\n<p>A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated that the threat of forced delisting for non-compliance has been lifted for US-listed Chinese biotechs. The PCAOB, acting under the remit of the US Holding Foreign Companies Accountable Act (HFCAA), reported that it has successfully secured complete access to inspect and investigate Chinese firms &#8220;for the first time in history.&#8221;<\/p>\n\n\n\n<p><strong>Inspection Details and Findings<\/strong><br>The PCAOB&#8217;s progress report followed the successful inspection of two auditors-KPMG Huazhen LLP in mainland China and PriceWaterhouseCoopers (PWC) in Hong Kong-covering eight different audit engagements. A large team of PCAOB inspectors visited China and Hong Kong from September this year and were given unprecedented access for a 9-week period to view complete audit work papers with no redactions and interview all personnel associated with such audits. The inspection uncovered &#8220;numerous potential deficiencies,&#8221; with final reports still being finalized.<\/p>\n\n\n\n<p><strong>Regulatory Context and Future Prospects<\/strong><br>The HFCAA, introduced by the US in 2020, requires any foreign-based company listed on US exchanges to allow auditors registered with the PCAOB to carry out full inspections of finances within 3 years or face delisting. The US Securities and Exchange Commission (SEC) began issuing notices to comply to around 200 Chinese companies-including several pharma and biotech companies such as BeiGene, Zai Lab, HutchMed, and I-Mab-from March 2022. The US and Chinese governments reached a landmark agreement to allow PCAOB inspections in August. As long as the PCAOB continues to have access to China-based auditors, the threat of automatic delisting has been removed for now.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[61,4],"tags":[30,72],"class_list":["post-23473","post","type-post","status-publish","format-standard","hentry","category-legal-ip","category-policy-regulatory","tag-biotech","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PCAOB Report Signals Relief for US-Listed Chinese Biotechs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated that the threat of forced delisting for non-compliance has been lifted for US-listed Chinese biotechs. The PCAOB, acting under the remit of the US Holding Foreign Companies Accountable Act (HFCAA), reported that it has successfully secured complete access to inspect and investigate Chinese firms &quot;for the first time in history.&quot;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23473\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PCAOB Report Signals Relief for US-Listed Chinese Biotechs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23473\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-20T13:21:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T13:24:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23473#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23473\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PCAOB Report Signals Relief for US-Listed Chinese Biotechs\",\"datePublished\":\"2022-12-20T13:21:00+00:00\",\"dateModified\":\"2025-01-27T13:24:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23473\"},\"wordCount\":267,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"IPO\"],\"articleSection\":[\"Legal \\\/ IP\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23473#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23473\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23473\",\"name\":\"PCAOB Report Signals Relief for US-Listed Chinese Biotechs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-20T13:21:00+00:00\",\"dateModified\":\"2025-01-27T13:24:41+00:00\",\"description\":\"A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated that the threat of forced delisting for non-compliance has been lifted for US-listed Chinese biotechs. The PCAOB, acting under the remit of the US Holding Foreign Companies Accountable Act (HFCAA), reported that it has successfully secured complete access to inspect and investigate Chinese firms \\\"for the first time in history.\\\"\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23473#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23473\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23473#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PCAOB Report Signals Relief for US-Listed Chinese Biotechs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PCAOB Report Signals Relief for US-Listed Chinese Biotechs - Insight, China&#039;s Pharmaceutical Industry","description":"A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated that the threat of forced delisting for non-compliance has been lifted for US-listed Chinese biotechs. The PCAOB, acting under the remit of the US Holding Foreign Companies Accountable Act (HFCAA), reported that it has successfully secured complete access to inspect and investigate Chinese firms \"for the first time in history.\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23473","og_locale":"en_US","og_type":"article","og_title":"PCAOB Report Signals Relief for US-Listed Chinese Biotechs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23473","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-20T13:21:00+00:00","article_modified_time":"2025-01-27T13:24:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23473#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23473"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PCAOB Report Signals Relief for US-Listed Chinese Biotechs","datePublished":"2022-12-20T13:21:00+00:00","dateModified":"2025-01-27T13:24:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23473"},"wordCount":267,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","IPO"],"articleSection":["Legal \/ IP","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23473#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23473","url":"https:\/\/flcube.com\/?p=23473","name":"PCAOB Report Signals Relief for US-Listed Chinese Biotechs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-20T13:21:00+00:00","dateModified":"2025-01-27T13:24:41+00:00","description":"A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated that the threat of forced delisting for non-compliance has been lifted for US-listed Chinese biotechs. The PCAOB, acting under the remit of the US Holding Foreign Companies Accountable Act (HFCAA), reported that it has successfully secured complete access to inspect and investigate Chinese firms \"for the first time in history.\"","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23473#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23473"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23473#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PCAOB Report Signals Relief for US-Listed Chinese Biotechs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23473"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23473\/revisions"}],"predecessor-version":[{"id":23474,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23473\/revisions\/23474"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}